Product image of Insuman Rapid (Insulin Human) supplied by GNH India

Insuman Rapid

Active Ingredient:
Insulin Human
Origin:
EU

Insuman Rapid (Insulin Human)

Insulin human, the active ingredient in Insuman Rapid, is an insulin presented as a sterile solution for subcutaneous and intravenous use. It is employed to lower blood glucose levels in patients with diabetes mellitus, including both type 1 and type 2 disease.

GNH India supplies Insuman Rapid as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide and ensures timely delivery to meet clinical needs.

Manufacturer / TM Owner

Sanofi-Aventis Deutschland Gmbh

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Insuman Rapid is a rapid‑acting insulin that helps control hyperglycemia in diabetes mellitus.

  • Type 1 diabetes mellitus: provides rapid‑acting insulin replacement to achieve target glucose ranges, supporting basal‑bolus regimens, reducing episodes of acute hyperglycemia, and improving overall metabolic control.
  • Type 2 diabetes mellitus: used as part of intensive insulin therapy when oral agents are insufficient, facilitating post‑prandial glucose control, lowering HbA1c levels, and enhancing overall glycemic management.

How It Works

  • Insuman Rapid contains human insulin, which binds to insulin receptors on cell membranes, activating the receptor’s intrinsic tyrosine kinase activity. This triggers intracellular signaling cascades that promote translocation of GLUT‑4 transporters to the cell surface, enhancing glucose uptake in muscle and adipose tissue, while suppressing hepatic glucose production, thereby lowering blood glucose concentrations.

Side Effects

Insuman Rapid may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

  • Hypoglycemia: low blood glucose episodes, especially if dosing mismatches meals.
  • Injection site reactions: redness, swelling, or itching at the injection site.
  • Weight gain: modest increase associated with insulin therapy.
  • Lipodystrophy: localized changes in subcutaneous fat with repeated injections.

Serious or Rare Side Effects

  • Severe hypoglycemia with neuroglycopenic symptoms.
  • Allergic reactions: urticaria, angioedema, or anaphylaxis.
  • Insulin edema: fluid retention leading to peripheral swelling.

Precautions & Warnings

When using Insuman Rapid, healthcare professionals should observe several safety considerations to minimize risks.

  • Blood glucose monitoring: check levels frequently to adjust dose and avoid hypoglycemia.
  • Dose adjustment during illness: increase monitoring and consider dose changes when patients are febrile or have reduced intake.
  • Hypoglycemia unawareness: exercise caution in patients who cannot perceive low glucose symptoms.
  • Renal or hepatic impairment: may require dose reduction and closer monitoring.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Insuman Rapid can interact with other medicines, affecting glucose control or masking symptoms.

Major Interactions (Avoid)

  • Beta‑blockers: may mask hypoglycemia symptoms, requiring careful monitoring.
  • MAO inhibitors: can potentiate insulin’s glucose‑lowering effect, increasing hypoglycemia risk.

Moderate Interactions (Monitor Closely)

  • Thiazide diuretics: may raise blood glucose, necessitating dose adjustments.
  • Corticosteroids: can increase insulin resistance, requiring higher insulin doses.
  • Oral contraceptives: may affect glucose metabolism, requiring closer glucose monitoring.

Frequently Asked Questions

Insuman Rapid is a rapid‑acting insulin formulation used to lower elevated blood glucose levels in patients with diabetes mellitus, including both type 1 and type 2 diabetes, as part of a comprehensive glycemic‑control regimen.

Insulin human mimics the body’s natural insulin by binding to insulin receptors on muscle, fat and liver cells. This activates intracellular pathways that increase glucose uptake and storage while suppressing hepatic glucose production, resulting in reduced blood‑sugar concentrations.

The dose of Insuman Rapid is individualized by the prescribing clinician based on factors such as the patient’s weight, current blood‑glucose levels, carbohydrate intake, activity level, and response to therapy. No fixed dosing schedule is provided here.

Insulin, including insulin human, is generally considered the treatment of choice for diabetes in pregnancy because it does not cross the placenta in significant amounts. However, use should be guided by a qualified healthcare professional, and breastfeeding mothers should follow medical advice.

To order Insuman Rapid, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and import documentation.

Insuman Rapid contains human insulin, whereas many newer rapid‑acting analogues are modified molecules (e.g., insulin lispro, aspart). Human insulin has a well‑established safety profile and is often less expensive, but some analogues may have slightly faster onset or reduced variability in absorption.

Insuman Rapid should be stored at 2‑8 °C (refrigerated), protected from light, and must not be frozen or shaken. Once in use, the vial or pen may be kept at controlled room temperature for a limited period as specified in the product labeling.

Insuman Rapid is administered by subcutaneous injection, typically into the abdomen, thigh, or upper arm, or intravenously in a clinical setting. The injection technique and site rotation should follow standard insulin‑administration guidelines provided by the prescriber.

The most serious risks include severe hypoglycemia, which can lead to loss of consciousness or seizures, and allergic reactions ranging from urticaria to anaphylaxis. Prompt recognition and medical intervention are essential if these events occur.

Insuman Rapid should be avoided in individuals with known hypersensitivity to human insulin or any excipients in the formulation, and in patients with severe hypoglycemia unawareness unless closely supervised. Clinical judgment is required for patients with certain medical conditions.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Insulin Human

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT